ArticlePlant cell reports2025
GmAP2 enhances plant tolerance to aluminum toxicity and phosphorus deficiency in Arabidopsis.
Article in Plant cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adaptation mechanisms of low-phosphorus stress in plants: physiological responses, molecular regulation, and future perspectives.Frontiers in plant science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
key messageOverexpression of the GmAP2 gene regulates several aspects of gene expression in Arabidopsis, including acid-aluminum stress, low-phosphorus stress, ERF family transcription factors, ABA signaling, and genes related to lateral root development. The overexpression of GmAP2 can help plants mitigate the effects of aluminum toxicity and increase their tolerance to low-phosphorus stress. Ethylene response factors (ERFs) represent one of the largest transcription factor families in plants and are involved in regulating biotic and abiotic stresses, as well as growth and development in higher plants. In this study, the soybean GmAP2 gene, encoding the AP2/ERF transcription factor, is a downstream gene of GsMYB7, which enhances soybean tolerance to aluminum toxicity under acidic conditions, referred to as acid-aluminum stress. The expression pattern of GmAP2, which is constitutive and rich in roots, was upregulated under acid-aluminum and low-phosphorus stress. The resistance phenotypes of the wild-type and GmAP2-overexpressing lines were investigated by treatment with acid-aluminum plates and low-phosphorus plates, respectively. The results revealed significant differences between the GmAP2 transgenic lines and the wild type, and compared with the wild-type plants, the genetically modified plants presented significantly better physiological indicators, such as fresh weight, root length, and number of lateral roots. Under acid-aluminum stress, changes in weight, MDA content, and proline content in Arabidopsis thaliana were evaluated. The genes associated with these pathways, including genes related to the acid-aluminum response (AtALMT, AtALS3, AtSTOP1, and AtMATE), ERF family (AtERF6, AtERF15, AtERF5, and AtERF109), and/or ABA response (AtABI5, AtRD29A, AtRAP2.6, AtABI1, and AtABI2), are significantly regulated. In the context of low-phosphorus stress, a comprehensive analysis of the regulatory landscape revealed significant alterations in genes involved in these pathways, including low phosphorus-responsive genes (AtPHT1; 1, AtPHO1, AtPHR1, and AtMGD2), ERF family genes (AtERF1, AtERF6, AtERF13, and AtERF109), and/or genes associated with lateral root development (AtKCS16). These regulatory changes occurred in response to low-phosphorus stress. These results provide a basis for breeding soybean varieties that can increase their tolerance to the stresses of aluminum toxicity and low phosphorus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.